SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

BRAVECTO

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercialized. The original BRAVECTO chewable was approved in 2014. The latest formulation, BRAVECTO Quantum (12-month injectable), was FDA-approved on July 10, 2025.
Why 3/10
No hard, dated binary catalyst (PDUFA, pivotal readout) is scheduled for any BRAVECTO product in the next ~12 months. The franchise is fully approved and commercialized. As a small part of a $65B+ diversified pharma, even a material sales shift in this product line would have minimal impact on Merck's stock price. Score is 3.
Actionable Insight NEUTRAL

With no upcoming PDUFA or pivotal readout for BRAVECTO, the next event to watch for this product line is the ongoing NARB referral to the FTC and FDA over Bravecto Quantum marketing claims, which could result in labeling or advertising restrictions. Quarterly earnings reports (next: Q4 2026, late January 2027) will show whether Bravecto Quantum is gaining traction with veterinarians and whether the established chewable/topical franchise is holding market share against Zoetis's NexGard and Simparica Trio.

Price Chart

Loading chart...

Executive Summary

BRAVECTO is Merck Animal Health's blockbuster flea and tick protection franchise for dogs and cats, with $1.1 billion in 2025 sales. Its active ingredient, fluralaner, belongs to the isoxazoline class and is available in oral chews (12-week, 1-month), topical solutions (Bravecto Plus includes moxidectin for heartworm), and the recently approved Bravecto Quantum, a once-yearly injectable launched in July 2025. The Quantum label was expanded in March 2026 to cover two additional tick species. BRAVECTO faces stiff competition from Zoetis's NexGard and Simparica Trio and Elanco products. An ongoing ad dispute with Elanco over Quantum's 'once-a-year' claims was referred to the FTC and FDA by the NARB in May 2026. As a small but steady contributor within Merck's $65B+ diversified revenue base, BRAVECTO has no near-term binary catalysts to drive outsized stock moves.

How It Works

Fluralaner is an isoxazoline-class antiparasitic that works by overstimulating the nervous system of fleas and ticks, causing paralysis and death. It is absorbed into the pet's bloodstream and kills parasites when they bite. Different formulations provide protection ranging from one month (chews) up to 12 months (Bravecto Quantum injectable).

Trial Status

BRAVECTO is fully approved and marketed in the US and globally across multiple formulations. The newest formulation, Bravecto Quantum, received FDA approval on July 10, 2025, as the first-ever once-yearly flea and tick injectable for dogs. A label expansion was approved on March 18, 2026, adding two tick species.

The Two-Sided Case

▲ Bull Case3
Bravecto Quantum, approved July 2025 as the first and only once-yearly injectable flea/tick treatment for dogs, represents a significant innovation that addresses the pet owner compliance problem. It offers veterinarians a product administered in-clinic that guarantees 12 months of coverage.
The FDA expanded Bravecto Quantum's label in March 2026 to cover two additional tick species (Asian longhorned tick and Gulf Coast tick), broadening its addressable market in regions where those ticks are emerging threats.
The BRAVECTO franchise generated $1.1 billion in 2025 and is a core part of Merck Animal Health, which posted growing sales through 2026 including $1.68 billion in Q3 2026 alone.
▼ Bear Case3
The National Advertising Review Board (NARB) referred Merck to the FTC and FDA in May 2026 for failing to comply with recommendations to modify once-a-year dosing claims for Bravecto Quantum, because the product provides only 8 months of protection against lone star ticks vs. 12 months for other species. This regulatory advertising dispute could lead to enforcement action.
BRAVECTO line sales were essentially flat in 2025 at $1.1 billion (1% growth), suggesting the core franchise may be maturing and facing competition from Zoetis's NexGard ($1.5B) and Simparica Trio (>$1B in U.S. sales).
As a small part of Merck's $65B+ total revenue (Animal Health is about $7B of that), BRAVECTO's performance has very limited ability to move Merck's stock price independently.

Upcoming Catalysts

  • FTC/FDA enforcement outcome following NARB referral over Bravecto Quantum advertising claims (timing uncertain)
  • Quarterly earnings reports will disclose BRAVECTO line sales performance relative to growing competition

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 12

Hover a chip for the title
1 merck.com2 fda.gov3 merck-animal-health-usa.com4 merck.com5 bbbprograms.org6 bbbprograms.org7 cnbc.com8 merck.com9 us.bravecto.com10 animaldrugsatfda.fda.gov11 animalhealthnews.com12 merck.com